ethinyl estradiol has been researched along with Dyslipidemias in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Curtis, KM; Dragoman, M; Gaffield, ME | 1 |
| Alvarez-Blasco, F; Botella-Carretero, JI; Escobar-Morreale, HF; Lasunción, MA; Luque-Ramírez, M; Martínez-Bermejo, E | 1 |
1 review(s) available for ethinyl estradiol and Dyslipidemias
| Article | Year |
|---|---|
Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes.
Topics: Contraception; Contraception Behavior; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Dyslipidemias; Ethinyl Estradiol; Female; Humans; Myocardial Infarction; Patient Satisfaction; Progestins; Stroke; Venous Thromboembolism | 2016 |
1 trial(s) available for ethinyl estradiol and Dyslipidemias
| Article | Year |
|---|---|
Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Topics: Administration, Oral; Adult; Androgen Antagonists; Androgens; Blood Glucose; Cardiovascular Diseases; Cyproterone Acetate; Drug Combinations; Dyslipidemias; Ethinyl Estradiol; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Metformin; Polycystic Ovary Syndrome; Risk Factors | 2007 |